Pharmacological inhibition of the Ras pathway in patients with hepatocellular carcinoma (HCC) has shown promising results, supporting the development of additional treatment strategies that target this pathway. Nguyen et al. previously reported a transgenic zebrafish model constitutively expressing krasV12; now, they improve on this system by developing a model that allows krasv12 to be inducibly expressed, giving 100% tumour incidence that can be temporally controlled. They use this system to show that the Raf-MEK-ERK and PI3K-AKT-mTOR signalling pathways are involved in HCC, and that inhibitors of these pathways might be promising therapeutics. Page 63

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (, which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.